Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
Public ClinicalTrials.gov record NCT03628066. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients With Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will look at the safety and effectiveness of the combination of palbociclib and letrozole and ovarian suppression for premenopausal patients who have ER-positive/HER2-negative breast cancer that has not yet been treated.
Study identification
- NCT ID
- NCT03628066
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Interventions
- Letrozole Drug
- Palbociclib Drug
- Goserelin Drug
- Oncotype DX Breast Recurrence Score Diagnostic Test
Drug · Diagnostic Test
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 21, 2018
- Primary completion
- Nov 29, 2020
- Completion
- Jan 29, 2021
- Last update posted
- Apr 19, 2022
2018 – 2021
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Breast Cancer Care Specialist | Fountain Valley | California | 92708 | — |
| Orange Coast Blood and Cancer Care | Fountain Valley | California | 92708 | — |
| Saddleback Memorial Medical Center | Laguna Hills | California | 92653 | — |
| Coast Hematology-Oncology Associates Medical Group | Long Beach | California | 90806 | — |
| Long Beach Memorial Medical Center | Long Beach | California | 90806 | — |
| Oncology Hematology Consultants | Long Beach | California | 90806 | — |
| Cancer Care Specialists of Central Illinois | Decatur | Illinois | 62526 | — |
| Avera Cancer Institute-Sioux Falls | Sioux Falls | South Dakota | 57105 | — |
| Lester and Sue Smith Breast Center | Houston | Texas | 77030 | — |
| West Virginia University | Morgantown | West Virginia | 26506 | — |
| Froedtert Hospital | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03628066, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2022 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03628066 live on ClinicalTrials.gov.